tetano
Editor, Senior Moderator
Front Immunol
. 2022 Oct 21;13:1046352.
doi: 10.3389/fimmu.2022.1046352. eCollection 2022.
Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis
Meitong Liu[SUP] 1 [/SUP], Huijuan Wang[SUP] 2 [/SUP], Lu Liu[SUP] 2 [/SUP], Saijin Cui[SUP] 1 [/SUP], Xiangran Huo[SUP] 1 [/SUP], Zhuoyun Xiao[SUP] 1 [/SUP], Yaning Zhao[SUP] 1 [/SUP], Bin Wang[SUP] 2 [/SUP], Guoqiang Zhang[SUP] 2 3 [/SUP], Na Wang[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) have brought great disaster to mankind, and there is currently no globally recognized specific drug or treatment. Severe COVID-19 may trigger a cytokine storm, manifested by increased levels of cytokines including interleukin-17 (IL-17), so a new strategy to treat COVID-19 may be to use existing IL-17 inhibitors, which have demonstrated efficacy, safety and tolerability in the treatment of psoriasis. However, the use of IL-17 inhibitors in patients with psoriasis during the COVID-19 pandemic remains controversial due to reports that IL-17 inhibitors may increase the risk of respiratory tract infections.
Objectives: The systematic review and meta-analysis aimed to evaluate the effect of IL-17 inhibitors on the risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis.
Methods: Databases (including Embase, PubMed, SCI-Web of Science, Scopus, CNKI, and the Cochrane Library) were searched up to August 23, 2022, for studies exploring differences in COVID-19 outcomes between psoriasis patients using IL-17 inhibitors and those using non-biologics. Two authors independently extracted data and assessed the risk of bias in a double-blind manner. The risk ratios (RRs) and 95% confidence intervals (CIs) were calculated and heterogeneities were determined by the Q test and I [SUP]2[/SUP] statistic. And the numbers needed to treat (NNTs) were calculated to assess the clinical value of IL-17 inhibitors in preventing SARS-CoV-2 infection and treating COVID-19.
Results: Nine observational studies involving 7,106 participants were included. The pooled effect showed no significant differences in the rates of SARS-CoV-2 infection (P = 0.94; I [SUP]2[/SUP] = 19.5%), COVID-19 hospitalization (P = 0.64; I [SUP]2[/SUP] = 0.0%), and COVID-19 mortality (P = 0.32; I [SUP]2[/SUP] = 0.0%) in psoriasis patients using IL-17 inhibitors compared with using non-biologics. Subgroup analyses grouped by age and COVID-19 cases, respectively, revealed consistent results as above. Meanwhile, the pooled NNTs showed no significant differences between the two groups in the clinical value of preventing SARS-CoV-2 infection and treating COVID-19.
Conclusion: The use of IL-17 inhibitors in patients with psoriasis does not increase the risk of SARS-CoV-2 infection or worsen the course of COVID-19.
Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022335195.
Keywords: COVID-19; NNT; interleukin-17 inhibitors; meta-analysis; psoriasis; systematic review.
. 2022 Oct 21;13:1046352.
doi: 10.3389/fimmu.2022.1046352. eCollection 2022.
Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis
Meitong Liu[SUP] 1 [/SUP], Huijuan Wang[SUP] 2 [/SUP], Lu Liu[SUP] 2 [/SUP], Saijin Cui[SUP] 1 [/SUP], Xiangran Huo[SUP] 1 [/SUP], Zhuoyun Xiao[SUP] 1 [/SUP], Yaning Zhao[SUP] 1 [/SUP], Bin Wang[SUP] 2 [/SUP], Guoqiang Zhang[SUP] 2 3 [/SUP], Na Wang[SUP] 1 [/SUP]
Affiliations
- PMID: 36389759
- PMCID: PMC9648142
- DOI: 10.3389/fimmu.2022.1046352
Abstract
Background: Coronavirus disease 2019 (COVID-19) have brought great disaster to mankind, and there is currently no globally recognized specific drug or treatment. Severe COVID-19 may trigger a cytokine storm, manifested by increased levels of cytokines including interleukin-17 (IL-17), so a new strategy to treat COVID-19 may be to use existing IL-17 inhibitors, which have demonstrated efficacy, safety and tolerability in the treatment of psoriasis. However, the use of IL-17 inhibitors in patients with psoriasis during the COVID-19 pandemic remains controversial due to reports that IL-17 inhibitors may increase the risk of respiratory tract infections.
Objectives: The systematic review and meta-analysis aimed to evaluate the effect of IL-17 inhibitors on the risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis.
Methods: Databases (including Embase, PubMed, SCI-Web of Science, Scopus, CNKI, and the Cochrane Library) were searched up to August 23, 2022, for studies exploring differences in COVID-19 outcomes between psoriasis patients using IL-17 inhibitors and those using non-biologics. Two authors independently extracted data and assessed the risk of bias in a double-blind manner. The risk ratios (RRs) and 95% confidence intervals (CIs) were calculated and heterogeneities were determined by the Q test and I [SUP]2[/SUP] statistic. And the numbers needed to treat (NNTs) were calculated to assess the clinical value of IL-17 inhibitors in preventing SARS-CoV-2 infection and treating COVID-19.
Results: Nine observational studies involving 7,106 participants were included. The pooled effect showed no significant differences in the rates of SARS-CoV-2 infection (P = 0.94; I [SUP]2[/SUP] = 19.5%), COVID-19 hospitalization (P = 0.64; I [SUP]2[/SUP] = 0.0%), and COVID-19 mortality (P = 0.32; I [SUP]2[/SUP] = 0.0%) in psoriasis patients using IL-17 inhibitors compared with using non-biologics. Subgroup analyses grouped by age and COVID-19 cases, respectively, revealed consistent results as above. Meanwhile, the pooled NNTs showed no significant differences between the two groups in the clinical value of preventing SARS-CoV-2 infection and treating COVID-19.
Conclusion: The use of IL-17 inhibitors in patients with psoriasis does not increase the risk of SARS-CoV-2 infection or worsen the course of COVID-19.
Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022335195.
Keywords: COVID-19; NNT; interleukin-17 inhibitors; meta-analysis; psoriasis; systematic review.